梯瓦制药一季度每股收益0.52美元，比分析师普遍预期的0.48美元高出8.33%，同比增长了8.33%。
一季度销售额为38.9亿美元，比分析师普遍预期的40亿美元低2.78%，同比增长了1.89%。
梯瓦制药预计全年营收168亿美元至172亿美元，市场预估172.2亿美元，此前预计168亿美元至174亿美元。
梯瓦制药预计全年调整后每股收益2.45美元至2.65美元。
梯瓦制药仍然预测全年自由现金流16亿美元至19亿美元。
梯瓦制药预计全年调整后EBITDA 47亿美元至50亿美元，市场预估48.9亿美元，此前预计45亿美元至50亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.